PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer

Table 1

Univariate and multivariate Cox regression analyses of PLOD2 expression for overall survival (OS) in patients with cervical cancer from The Cancer Genome Atlas (TCGA) dataset.

Characteristics	Total ()	Univariate analysis		Multivariate analysis
		Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value
Clinical stage (stage III and stage IV vs. stage I and stage II)	302	2.329 (1.432-3.788)	<0.001	1.543 (0.762-3.126)	0.228
BMI (>25 vs. ≤25)	263	0.599 (0.348-1.033)	0.065	0.841 (0.433-1.631)	0.608
Birth control pill history (yes vs. no)	160	0.674 (0.325-1.398)	0.289
Age (>50 vs. ≤50)	309	1.281 (0.805-2.037)	0.296
Primary therapy outcome (CR vs. PD and SD and PR)	221	0.072 (0.039-0.133)	<0.001	0.069 (0.033-0.144)	<0.001